Completed PHASE2 INTERVENTIONAL 2-arm NCT02196961

Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation (ADMEC-O)

Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With Immune Checkpoint Blocking Antibodies (Nivolumab, Opdivo®; Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation

Sponsor: Bristol-Myers Squibb

Conditions Merkel Cell Carcinoma

Interventions Nivolumab

Updated 13 times since 2017 Last updated: Apr 6, 2025 Started: Jun 30, 2014 Primary completion: Aug 31, 2024 Completion: Aug 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Merkel Cell Carcinoma, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 13 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

13 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
May 2025 — Sep 2025 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2024 — May 2025 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Dec 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

▶ Show 8 earlier versions

Sep 2022 — Dec 2023 [monthly]

Active Not Recruiting PHASE2
Feb 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE2
Jan 2021 — Feb 2022 [monthly]

Active Not Recruiting PHASE2
Nov 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2019 — Nov 2020 [monthly]

Recruiting PHASE2
Jun 2018 — Oct 2019 [monthly]

Recruiting PHASE2
Sep 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Sep 2017 [monthly]

Recruiting PHASE2

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Prof. Dr. med. Dirk Schadendorf

Data source: University Hospital, Essen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Berlin, Germany , Buxtehude, Germany , Dresden, Germany , Erfurt, Germany , Essen, Germany , Freiburg im Breisgau, Germany , Gera, Germany , Hanover, Germany , Heidelberg, Germany and 9 more locations